See the DrugPatentWatch profile for Segluromet
What is Segluromet and what is its generic name?
Segluromet is a brand-name medication that combines two active ingredients: sitagliptin and metformin [1]. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin is a biguanide [1]. Both components work together to improve blood sugar control in adults with type 2 diabetes [1]. The generic name for Segluromet would be sitagliptin and metformin [1].
When is the patent for Segluromet expected to expire?
The patents for Segluromet are complex, involving patents for both the sitagliptin and metformin components, as well as for the combination product itself [2]. Patent expiry dates can be influenced by various factors, including patent challenges and exclusivity periods granted by regulatory bodies. For detailed information on specific patent expiry dates, DrugPatentWatch.com provides comprehensive data on pharmaceutical patents [2].
Who makes Segluromet?
Segluromet is manufactured by Merck & Co. [3].
How do sitagliptin and metformin work together?
Sitagliptin works by increasing the levels of incretin hormones, which help regulate blood sugar [1]. Metformin works by decreasing the amount of glucose produced by the liver and increasing the body's sensitivity to insulin [1]. Together, these mechanisms help to lower blood glucose levels [1].
What are the alternatives to Segluromet?
There are several classes of medications available for managing type 2 diabetes, including other DPP-4 inhibitors, sulfonylureas, thiazolidinediones, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists [4]. Jardiance, also a combination drug for type 2 diabetes, contains empagliflozin and linagliptin and is an alternative option [5]. The best alternative depends on individual patient needs, medical history, and physician recommendations.